spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman


Professor Howell has over 20 years’ life science commercialisation experience, supporting companies’ development and profitability. He founded Innova Partnerships in 2006, where he has been instrumental in creating over a dozen life science start-ups and raised in excess of Ł100m in financing. Steve oversaw the exit of Innova Biosciences in 2016-2017 to SYGNIS AG, Innova Partnerships’ second exit. He has held positions at Unilever plc, and was previously Director of Business Development at Alere Inc. and Research Director at Unipath Ltd. In 2015 he was made Visiting Professor of Commercial Innovation at King's College, London.

Professor Steve Howell, Non-Executive Chairman, Arcis Biotechnology, commented:“The Arcis sample preparation technology has enormous potential across many application areas, including diagnostics and genetic understanding. I am excited to be joining the team as we build the business to bring products to market that will have real and positive impact on patient quality of life.”

Paul Foulger, Non-Executive Director, Arcis Biotechnology, said:"We have an exciting opportunity to build a world-leading and highly valuable biotech based on Arcis’ current technology platform and future ambitions. Steve’s considerable experience, expertise and network will make a significant contribution to achieving that goal and delivering maximum value to shareholders.”

Peter Whitehurst, CEO, Arcis Biotechnology, said: “I would like to thank Paul for his time as interim Chairman, and for working with the Executive Directors to bring Steve in for the next exciting phase of development at Arcis.”

The appointment of Professor Howell as Non-Executive Chairman follows the Company’s recent announcements of strategic distribution and licensing agreements, with Opentrons and Mirnax Biosens respectively. These agreements extend the reach of Arcis’ sample preparation and preservation technology in two areas of the life sciences industry – high throughput sample prep with robotics, and the development of early disease diagnostics.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

[Noáin, Spain, September 30, 2020]3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director.
More info >>


White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement